Effect of an Enhanced Recovery After Surgery Program on Opioid Use and Patient-Reported Outcomes

Larissa A. Meyer, Javier Lasala, Maria D. Iniesta, Alpa M. Nick, Mark F. Munsell, Qiuling Shi, Xin Shelley Wang, Katherine Cain, Karen H. Lu, Pedro T. Ramírez

Obstetrics and Gynecology · 2018 · 155 citations · 31 references

Concepts

TL;DR

Enhanced recovery after surgery (ERAS) programs aim to improve perioperative outcomes, particularly opioid use and patient‑reported recovery, and this study was initiated as a quality‑improvement effort in November 2014. The study investigated the effect of an ERAS program on perioperative outcomes, focusing on opioid consumption and patient‑reported outcomes during the immediate and extended postoperative periods. The authors compared 607 women undergoing open gynecologic surgery before and after ERAS implementation, with 293 patients’ post‑operative symptoms assessed using the MD Anderson Symptom Inventory‑Ovarian Cancer, and median age was 58 years. ERAS implementation reduced median length of stay by 25%, cut opioid consumption by 72% (with 16% opioid‑free up to POD 3), improved fatigue and functional interference scores, and accelerated recovery, all without increasing pain scores, complications, readmissions, or reoperations.

Abstract

To investigate the effect of an enhanced recovery after surgery (ERAS) program on perioperative outcomes with an emphasis on opioid consumption and patient-reported outcomes in the immediate and extended postoperative periods.We initiated our ERAS program as part of a quality improvement initiative in November 2014. We compared clinical outcomes among a cohort of 607 women undergoing open gynecologic surgery before or after implementation of ERAS. For 293 patients, patient-reported outcomes were compared using the MD Anderson Symptom Inventory-Ovarian Cancer.Median age was 58 years (range 18-85 years). Median length of stay decreased by 25% for patients in the ERAS pathway (P<.001). Overall, patients in the ERAS group had a 72% reduction in median opioid consumption and 16% were opioid-free during admission up to postoperative day 3 (P<.001). There was no difference in pain scores (P=.80). Patients on ERAS reported less fatigue (P=.01), interference with walking (P=.003), and total interference (composite score of physical and affective measures) during hospitalization (P=.008). After discharge, those on the ERAS pathway demonstrated a significantly shorter median time to return to no or mild fatigue (10 vs 30 days, P=.03), mild or no interference with walking (5 vs 13 days, P=.003), and mild to no total interference (3 vs 13 days, P=.02). There were no significant differences in complications, rates of readmission, or reoperation between the pre- and post-ERAS groups.Implementation of an ERAS program was associated with significantly decreased opioid use after surgery and improvement in key patient-reported outcomes associated with functional recovery after surgery without compromising pain scores.

References

31